Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous BMA and BMAC in Parkinson's Disease and Parkinson-Plus Syndromes
NCT07751640Phase 2Active, not recruiting
- Sponsor
- Apeiron Biologics
- Start
- May 2025
- Primary completion
- Sep 2026
- Countries
- 1
01
Overview
A Phase 2 trial of autologous bone marrow aspirate in Parkinson's disease (PD), Parkinson plus syndrome (PPS), sponsored by Apeiron Biologics. Started May 2025; status: active, not recruiting.
02
Drugs
autologous bone marrow aspirate
03
Conditions
Parkinson's disease (PD)Parkinson plus syndrome (PPS)
Beyond the preview
Go deeper on NCT07751640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07751640.